Low-level laser therapy prevents medication-related osteonecrosis of the jaw-like lesions via IL-1RA-mediated primary gingival wound healing

• DOI: 10.1186/s12903-022-02678-1
• Publication Date: 2023-01-10T15:04:15Z
• Authors: Yi Zheng; Xian Dong; Shuo Chen; Yang He; Jingang An; Meng Liu; Linhai He; Yi Zhang
• Keywords: Radiology, Nuclear Medicine and Imaging; Zoledronic Acid; Mice; Medication-related osteonecrosis of the jaw; Low-Level Laser Therapy; Pathology; Internal medicine; Low level laser therapy; Bone healing; 0303 health sciences; Bone Density Conservation Agents; Diphosphonates; Physics; RK1-715; 3. Good health; Low-level light therapy; Tumor necrosis factor-α; Interleukin-1 receptor antagonist; Oncology; Medicine; Bisphosphonate-Associated Osteonecrosis of the Jaw; Oral Surgery; Zoledronate; Classification and Management of Odontogenic Tumors; Osteonecrosis of the Jaw; Wound healing; Laser; 03 medical and health sciences; Laser therapy; Health Sciences; Bisphosphonates in Cancer Treatment and Bone Health; Animals; Bisphosphonate; Low-Level Light Therapy; Inflammation; Wound Healing; Osteonecrosis of the jaw; Research; FOS: Clinical medicine; Low-Level Laser Therapy in Biomedical Applications; Interleukin-1 beta; Optics; X-Ray Microtomography; Molar; Interleukin 1 Receptor Antagonist Protein; Dentistry; Gingival Diseases; Tooth Extraction; Quality of Life; Osteoporosis; Surgery; Oral and maxillofacial surgery; Angiogenesis

Abstract Background Medication-related osteonecrosis of the jaw (MRONJ) is a serious debilitating disease caused by anti-resorption and anti-angiogenesis drugs, significantly affecting patients' quality life. Recent studies suggested that primary gingival wound healing may effectively prevent development MRONJ. This study aimed to evaluate effects low-level light therapy (LLLT) on promoting in extraction sockets MRONJ-like mice preventing occurrence Furthermore, we explored underlying mechanisms. Methods Mice were randomly divided into Ctrl, Zol, Zol + LLLT groups. Administration zoledronate tooth bilateral maxillary second molars used build MRONJ model, was locally administered examine effect LLLT. Next, explore function IL-1RA, performed with interleukin-1 receptor antagonist (IL-1RA) neutralizing antibody (named IL-1RA NAb group) or negative control antibodies for subsequent rescue animal experiments. Stereoscope observations, micro-computed tomography, histological examination conducted bone regeneration sockets. The migration capacities zoledronate-treated epithelial cells assessed vitro. Results promoted without exposed necrotic bone. Micro-computed tomography results showed higher volume mineral density after Histology analysis complete coverage, obvious regeneration, reduced soft tissue inflammation, down-regulated pro-inflammation cytokines, like beta (IL-1β) tumor necrosis factor-α (TNF-α), up-regulated expression group. assay further might be partially abolished antibodies. In vitro demonstrated accelerated cell migration. Conclusions promote contribute extractions lesions via IL-1RA-mediated signaling suppression.